Febus 40

Indications

Febus 40 is used to treat hyperuricemia in gout patients on a long-term basis. Febuxostat is not recommended for asymptomatic hyperuricemia therapy.

 

Pharmacology

Febus 40 is a selective xanthine oxidase (XO) inhibitor that is non-purine. It lowers serum uric acid levels by blocking the enzyme xanthine oxidase, which produces uric acid. Xanthine oxidase converts hypoxanthine to xanthine, which is then converted to uric acid. At therapeutic dosages, Febuxostat is unlikely to inhibit other enzymes involved in purine and pyrimidine production and metabolism.

 

Dosage & Administration

Febuxostat is taken once a day in doses of 40 mg or 80 mg. Febuxostat is prescribed at a starting dose of 40 mg once daily. Febuxostat can be taken with or without meals, and it is not affected by the use of antacids. When giving Febuxostat to individuals with mild to severe renal or hepatic impairment, there is no need to alter the dose.

 

Interaction

When Febuxostat is taken with azathioprine, mercaptopurine, or theophylline, the plasma concentrations of these medicines may rise, resulting in severe toxicity.

 

Contraindications

Febuxostat is not recommended for people who are using azathioprine, mercaptopurine, or theophylline.

 

Side Effects

Liver function problems, nausea, arthralgia, and rash are the most prevalent side effects linked with the usage of Febuxostat.

 

Pregnancy & Lactation

There are no sufficient and well-controlled trials in pregnant women in pregnancy category C. Only if the possible benefit outweighs the risk to the fetus should Febuxostat be used during pregnancy. This medication is not known to be excreted in human milk. When given to a breastfeeding mother, Febuxostat should be used with caution.

 

Precautions & Warnings

Gout Flare: When anti-hyperuricemic drugs, such as Febuxostat, are first started, an increase in gout flares is common. Febuxostat does not need to be stopped if gout flares up during treatment. For up to six months, prophylactic therapy (i.e., nonsteroidal anti-inflammatory medicine (NSAID) or colchicine at the start of treatment) may be effective.

Cardiovascular Events: In clinical trials, patients treated with febuxostat had a greater rate of cardiovascular thromboembolic events than those treated with allopurinol. Keep an eye out for signs and symptoms of a heart attack or a stroke.

Transaminase Elevation: In febuxostat-treated patients, transaminase levels have been found to be elevated. Regularly check your liver function tests.

 

Therapeutic Class

Medications are used to treat gout.

 

Storage Conditions

Keep the temperature below 30°C and away from light and moisture. Keep out of children's reach.

 

Pharmaceutical Name

ACI Limited

 

Generic

Febuxostat

 

Related Products

• Barif 40
• Febux-40